Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 6/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21491328 | 1.00 | HRH3 (0.34) | HRH3LMNAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL31472351 | 1.00 | HRH3 (0.34) | HRH3LMNAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL21491389 | 0.83 | PRKAB2 (0.38) | KMT2AMEN1GPR119 | |
| SCHEMBL31472408 | 0.83 | PRKAB2 (0.38) | KMT2AMEN1GPR119 | |
| SCHEMBL21491386 | 0.83 | PRKAB2 (0.38) | KMT2AMEN1GPR119 | |
| SCHEMBL24313232 | 0.77 | SLC6A2 (0.38) | HRH3KMT2AMEN1PDE2APDE10A | |
| SCHEMBL31472367 | 0.75 | ESR1 (0.38) | — | |
| SCHEMBL21491275 | 0.75 | ESR1 (0.38) | — | |
| SCHEMBL21517141 | 0.75 | HTR6 (0.34) | LMNAKMT2AMEN1 | |
| SCHEMBL29456552 | 0.75 | HTR6 (0.34) | LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| EP-4043460-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2024-06-05 | — | — | EP | disclosed |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| US-11440907-B1 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2022-09-13 | — | — | US | disclosed |
| EP-4043460-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2022-08-17 | — | — | EP | disclosed |
| EP-4043460-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2022-08-17 | — | — | EP | disclosed |
| EP-3784666-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3784666-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3784666-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| CN-112236428-A | Antiproliferative compounds and uses thereof | 默克专利股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | HRH3 4118/4885LMNA 1520/4885KMT2A 2819/4885 |
| US-12195453-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | HRH3 4118/4885LMNA 1520/4885KMT2A 2819/4885 |
| US-11440907-B1 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | HRH3 4118/4885LMNA 1520/4885KMT2A 2819/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | HRH3 4118/4885LMNA 1520/4885KMT2A 2819/4885 |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | HRH3 4118/4885LMNA 1520/4885KMT2A 2819/4885 |
| US-20250188070-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | HRH3 4118/4885LMNA 1520/4885KMT2A 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.